Literature DB >> 24947971

Biotransformation and in vivo stability of protein biotherapeutics: impact on candidate selection and pharmacokinetic profiling.

Michael P Hall1.   

Abstract

Historically, since the metabolism of administered peptide/protein drugs ("biotherapeutics") has been expected to undergo predictable pathways similar to endogenous proteins, comprehensive biotherapeutic metabolism studies have not been widely reported in the literature. However, since biotherapeutics have rapidly evolved into an impressive array of eclectic modalities, there has been a shift toward understanding the impact of metabolism on biotherapeutic development. For biotherapeutics containing non-native chemical linkers and other moieties besides natural amino acids, metabolism studies are critical as these moieties may impart undesired toxicology. For biotherapeutics that are composed solely of natural amino acids, where end-stage peptide and amino acid catabolites do not generally pose toxicity concerns, the understanding of biotherapeutic biotransformation, defined as in vivo modifications such as peripherally generated intermediate circulating catabolites prior to end-stage degradation or elimination, may impact in vivo stability and potency/clearance. As of yet, there are no harmonized methodologies for understanding biotherapeutic biotransformation and its impact on drug development, nor is there clear guidance from regulatory agencies on how and when these studies should be conducted. This review provides an update on biotherapeutic biotransformation studies and an overview of lessons learned, tools that have been developed, and suggestions of approaches to address issues. Biotherapeutic biotransformation studies, especially for certain modalities, should be implemented at an early stage of development to 1) understand the impact on potency/clearance, 2) select the most stable candidates or direct protein re-engineering efforts, and 3) select the best bioanalytical technique(s) for proper drug quantification and subsequent pharmacokinetic profiling and exposure/response assessment.
Copyright © 2014 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24947971     DOI: 10.1124/dmd.114.058347

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  16 in total

Review 1.  Ligand-Binding Assay Development: What Do You Want to Measure Versus What You Are Measuring?

Authors:  Andrew P Mayer; Charles S Hottenstein
Journal:  AAPS J       Date:  2015-12-15       Impact factor: 4.009

Review 2.  Proteolysis and Oxidation of Therapeutic Proteins After Intradermal or Subcutaneous Administration.

Authors:  Ninad Varkhede; Rupesh Bommana; Christian Schöneich; M Laird Forrest
Journal:  J Pharm Sci       Date:  2019-08-10       Impact factor: 3.534

Review 3.  Searching for the Pareto frontier in multi-objective protein design.

Authors:  Vikas Nanda; Sandeep V Belure; Ofer M Shir
Journal:  Biophys Rev       Date:  2017-08-10

4.  LC-MS Differential Analysis for Fast and Sensitive Determination of Biotransformation of Therapeutic Proteins.

Authors:  Ming Yao; Bingming Chen; Weiping Zhao; John T Mehl; Lingjun Li; Mingshe Zhu
Journal:  Drug Metab Dispos       Date:  2018-01-31       Impact factor: 3.922

Review 5.  In Vivo Stability of Therapeutic Proteins.

Authors:  Joachim Schuster; Atanas Koulov; Hanns-Christian Mahler; Pascal Detampel; Joerg Huwyler; Satish Singh; Roman Mathaes
Journal:  Pharm Res       Date:  2020-01-03       Impact factor: 4.200

Review 6.  What doesn't kill you makes you stranger: Dipeptidyl peptidase-4 (CD26) proteolysis differentially modulates the activity of many peptide hormones and cytokines generating novel cryptic bioactive ligands.

Authors:  Ahmed M Elmansi; Mohamed E Awad; Nada H Eisa; Dmitry Kondrikov; Khaled A Hussein; Alexandra Aguilar-Pérez; Samuel Herberg; Sudharsan Periyasamy-Thandavan; Sadanand Fulzele; Mark W Hamrick; Meghan E McGee-Lawrence; Carlos M Isales; Brian F Volkman; William D Hill
Journal:  Pharmacol Ther       Date:  2019-02-10       Impact factor: 12.310

7.  Pharmacokinetic Modelling of Human Recombinant Protein, p75ECD-Fc: A Novel Therapeutic Approach for Treatment of Alzheimer's Disease, in Serum and Tissue of Sprague Dawley Rats.

Authors:  Sally Kelliny; Larisa Bobrovskaya; Xin-Fu Zhou; Richard Upton
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2021-01-28       Impact factor: 2.441

8.  Genetically Encoded Quinone Methides Enabling Rapid, Site-Specific, and Photocontrolled Protein Modification with Amine Reagents.

Authors:  Jun Liu; Rujin Cheng; Ned Van Eps; Nanxi Wang; Takefumi Morizumi; Wei-Lin Ou; Paul C Klauser; Sharon Rozovsky; Oliver P Ernst; Lei Wang
Journal:  J Am Chem Soc       Date:  2020-09-25       Impact factor: 15.419

9.  Assessment of Antibody Stability in a Novel Protein-Free Serum Model.

Authors:  Joachim Schuster; Vinay Kamuju; Roman Mathaes
Journal:  Pharmaceutics       Date:  2021-05-22       Impact factor: 6.321

10.  Strategic internal covalent cross-linking of TNF produces a stable TNF trimer with improved TNFR2 signaling.

Authors:  Liqin Ban; Willem Kuhtreiber; John Butterworth; Yoshiaki Okubo; Éva S Vanamee; Denise L Faustman
Journal:  Mol Cell Ther       Date:  2015-08-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.